바이오프로세스 분석기 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Bioprocess Analyzers Market was valued at USD 2 billion in 2023 and is projected to grow at a CAGR of 11.5% from 2024 to 2032. Bioprocess analyzers are essential tools used to monitor and optimize bioprocesses, which involve the use of living cells or their components to produce products such as biopharmaceuticals, biofuels, and other biotechnology-driven goods. These analyzers help improve the quality, efficiency, and control of biotechnological processes, especially in biologics production. The ongoing advancements in biotechnology have led to the development of more sophisticated and automated bioprocess analyzers, further fueling market growth. Additionally, the growing demand for biosimilars, owing to their cost-efficiency compared to biologics, is a significant market growth driver.

Government support and funding also foster innovation in this sector, underscoring the increasing importance of these instruments in the biopharmaceutical industry. Based on analysis type, concentration detection emerged as the leading segment, generating USD 1.1 billion in revenue in 2023, with expectations for continued growth at a CAGR of 11.6%. Biologics production, including monoclonal antibodies and vaccines, relies on accurate measurements of critical parameters such as proteins, metabolites, and cell densities. This drives the demand for analyzers that can ensure consistent product quality and regulatory compliance.

By application, the market is divided into antibiotics, recombinant proteins, biosimilars, and other bioproducts. The antibiotics segment accounted for a significant 30.8% market share in 2023 and is anticipated to grow at a 10.2% CAGR over the forecast period. Antibiotic production involves intricate microbial fermentation processes that require precise environmental control. Bioprocess analyzers, equipped with advanced sensors, help monitor and maintain optimal fermentation conditions, such as oxygen levels, nutrient feed, and temperature, ultimately enhancing production efficiency.

In terms of regional growth, the North American bioprocess analyzers market is expected to reach USD 2 billion by 2032. The U.S. led the regional market in 2023, with a revenue share of USD 712.7 million. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the demand for biologics and personalized medicines. This, in turn, is boosting the need for bioprocess analyzers to improve production processes and maintain regulatory compliance in the development of these advanced therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for biopharmaceutical products
    • 3.2.1.2 Advancements in biotechnology and bioprocessing
    • 3.2.1.3 Increasing demand for biosimilars
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments
    • 3.2.2.2 Complexity and technical expertise
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard
• 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables & accessories

Chapter 6 Market Estimates and Forecast, By Analysis Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Substrate analysis
• 6.3 Metabolite analysis
• 6.4 Concentration detection

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Antibiotics
• 7.3 Recombinant proteins
• 7.4 Biosimilars
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Biopharmaceutical companies
• 8.3 CROs & CMOs
• 8.4 Research & academic institutes
• 8.5 Other End Use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 4BioCell GmbH & Co. KG
• 10.2 Agilent Technologies, Inc.
• 10.3 Danaher Corporation
• 10.4 Endress+Hauser Group Services AG
• 10.5 Eppendorf AG
• 10.6 F. Hoffmann-La Roche Ltd.
• 10.7 Nova Biomedical
• 10.8 Randox Laboratories Ltd.
• 10.9 Sartorius AG
• 10.10 Solida Biotech GmBH
• 10.11 SYSBIOTECH GmbH
• 10.12 Thermo Fisher Scientific Inc.
• 10.13 Xylem Inc.